Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. That said, here is one stock where Wall Street’s excitement appears well-founded and two where consensus estimates seem disconnected from reality.

Two Stocks to Sell:

SunOpta (STKL)

Consensus Price Target: $9.60 (49.8% implied return)

Committed to clean-label foods, SunOpta (NASDAQ: STKL) is a sustainability-focused food and beverage company specializing in the sourcing, processing, and packaging of organic products.

Why Does STKL Fall Short?

1. Products aren't resonating with the market as its revenue declined by 4.9% annually over the last three years
2. Smaller revenue base of $763.2 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
3. Easily substituted products (and therefore stiff competition) result in an inferior gross margin of 15.6% that must be offset through higher volumes

SunOpta is trading at $6.41 per share, or 26.5x forward P/E. If you’re considering STKL for your portfolio, see our FREE research report to learn more.

Enovis (ENOV)

Consensus Price Target: $52.20 (57.4% implied return)

With a focus on helping patients regain or maintain their natural motion, Enovis (NYSE: ENOV) develops and manufactures medical devices for orthopedic care, from injury prevention and pain management to joint replacement and rehabilitation.

Why Should You Sell ENOV?

1. Customers postponed purchases of its products and services this cycle as its revenue declined by 7.1% annually over the last five years
2. Negative returns on capital show management lost money while trying to expand the business, and its falling returns suggest its earlier profit pools are drying up
3. Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions

Enovis’s stock price of $33.17 implies a valuation ratio of 10.7x forward P/E. Dive into our free research report to see why there are better opportunities than ENOV.

One Stock to Watch:

Intuitive Surgical (ISRG)

Consensus Price Target: $582.10 (33.4% implied return)

Pioneering minimally invasive surgery since its first da Vinci system was FDA-cleared in 2000, Intuitive Surgical (NASDAQ: ISRG) develops and manufactures robotic-assisted surgical systems that enable minimally invasive procedures across various medical specialties.

Why Does ISRG Catch Our Eye?

1. System Placement averaged 11.4% growth over the past two years and imply healthy demand for its products
2. Forecasted revenue growth of 14.2% for the next 12 months indicates its momentum over the last two years is sustainable
3. Earnings per share have massively outperformed its peers over the last five years, increasing by 17.7% annually

At $436.36 per share, Intuitive Surgical trades at 52.1x forward P/E. Is now the time to initiate a position? See for yourself in our in-depth research report, it’s free.

High-Quality Stocks for All Market Conditions

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.